In the first half of 2025, a total of almost 12,900 SKUs (stock keeping units) of medicinal products were introduced to the Russian pharmaceutical market. Compared to Q1-Q2 2024, this figure increased by 322 items. The number of trademarks (TM) and INNs entering circulation also increased. In the first half of 2025, 4,300 different TM were shipped to the market (73 more than in the same period of 2024). These include examples of medicines that appeared on the Russian market for the first time in early 2025, such as the intravenous antibiotic Meronex (INN meropenem) from Altegra. At the time of the medicine's release (in February of this year), there were already about 17 brands from different companies with this active ingredient on the market.

Another example is Folicinate (INN calcium folinate), a medicine that reduces the toxicity of cytostatic therapy, from the domestic company Pharmasyntez. The company launched the medicine in February 2025 and became the seventh manufacturer of this medicine. Sanofi's MenQuadfi vaccine for the prevention of meningococcal infection in children aged 6 weeks and older was also launched on the market. Sanofi has also registered a vaccine in Russia under the name Menactra (for children aged 9 months and older), and its deliveries have also been registered this year.

The total number of INNs on the Russian market grew by 13 positions over the year, with the market receiving more than 1,900 items in Q1-Q2 alone. Among the new active substances that appeared on the market for the first time, we can highlight the hypoglycemic medicine tirzepatide, an analogue of the original medicine from Eli Lilly, Mounjaro, which is not registered in our country. At the beginning of this year, two domestic tirzepatide medicines received approval from the Ministry of Health: Tirzetta (Promomed) and Sejaro (Geropharm), both of which entered circulation a month after registration.

Another example of an INN that was not previously available on the domestic market is the NSAID loxoprofen, manufactured domestically and in India by the companies Loxon and Dr. Reddy's. The medicines were registered in Russia in 2024, but only entered the market in May-June of this year.

Another noteworthy example is medicines with the INN josamycin, which entered the market in 2025. The brands Vilpramycin (Promomed) and Josafen (Pharmstandard) are domestic analogues of the original antibiotic Wilprafen (Astellas). After Wilprafen was discontinued on the global market, domestic manufacturers localized the production of josamycin in our country, obtaining registration certificates in 2024.

The number of medicine items produced by Russian companies is more than twice the number of SKUs offered by foreign suppliers in the pharmaceutical market. Every year, the range of products localized in Russia grows. In Q1-Q2 2025, it increased by 222 SKUs compared to the same period last year and exceeded 9,000 items. The range of foreign products is also expanding (+134 items) and numbered more than 4,000 items in the period under review. It should be noted that until 2023, the number of SKUs of foreign companies on the Russian pharmaceutical market was steadily declining. From 2020 to 2023, the number of items decreased by 235, and only in 2024 did the growth of the range of foreign-made medicines resume. At the same time, judging by the dynamics, the intensity of this process is developing in an upward trend, although it still lags behind the activity of pharmaceutical companies localized in our country.

[1] Excluding funds for radiodiagnostics (EphMRA classification group T01G) and radioactive medical preparations (V03C), as well as medical gases.